Related Experiment Video
Updated: Sep 3, 2025
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
[First report in Peru on direct-acting antiviral therapy for chronic hepatitis C in HIV-positive patients]
Jaime Antonio Collins Camones1, Elena Rocío Chamorro Chirinos2, Fiorella Vanessa Loyola Salvatierra3
1Vicerrectorado de Investigación, Universidad San Ignacio de Loyola. Lima, Perú; Servicio de Infectología, Departamento de Medicina Interna, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud. Lima, Perú.
Insights
Direct-acting antivirals (DAAs) show optimal virologic response, tolerability, and safety for treating chronic hepatitis C in HIV-positive patients. This study highlights the effectiveness of sofosbuvir-based regimens in this population.
Area of Science:
- Hepatology
- Infectious Diseases
- Virology
Background:
- Chronic hepatitis C (HCV) is a significant concern in HIV-positive individuals.
- Direct-acting antivirals (DAAs) have revolutionized HCV treatment.
- Limited data exists on DAA efficacy in HIV-positive populations in Peru.
Purpose of the Study:
- To evaluate the clinical experience with DAAs for chronic hepatitis C in HIV-positive patients.
- To assess the sustained virologic response, tolerability, and safety of DAA therapy.
- To present the first clinical experience in Peru with DAAs in this specific patient group.
Main Methods:
- A prospective case series of 10 HIV-positive patients with chronic hepatitis C.
- Treatment duration was 12 weeks using sofosbuvir-based regimens (daclatasvir or velpatasvir combinations).
- Primary outcome: sustained virologic response (SVR) at 12 weeks post-therapy; secondary outcomes: tolerability and safety.
Main Results:
- Nine out of ten patients achieved undetectable HCV viral load (SVR).
- All patients had suppressed HIV viral load prior to DAA treatment.
- No adverse events related to tolerability or safety were reported during therapy.
Conclusions:
- DAAs, including sofosbuvir with daclatasvir or velpatasvir, are effective and safe for treating chronic hepatitis C in HIV-positive patients.
- This study represents the initial clinical experience with DAAs for this indication in Peru.
- Optimal virologic response, tolerability, and safety were observed in the presented case series.
Objective:
To present the clinical experience with direct-acting antivirals (DAAs) for chronic hepatitis C in HIV-positive patients.
Materials And Methods:
Longitudinal and prospective case series of HIV-positive patients treated with DAAs for chronic hepatitis C between May 2019 and April 2020 at the Infectious Diseases Service of Hospital G. Almenara, EsSalud. The primary outcome was sustained virologic response to hepatitis C virus (HCV) 12 weeks after completion of DAA therapy. Secondary outcomes were tolerability and safety.
Results:
Ten patients were included in the study, two were women (20%). Two patients had cirrhosis (20%). All patients had suppressed HIV viral load prior to DAA therapy. Patients received a 12-week regimen based on sofosbuvir: one with daclatasvir separately, and the remaining nine with velpatasvir combined in a single tablet per day. The sustained virological response of HCV was evaluable nine cases. In these, the HCV viral load was undetectable. No occurrences were recorded regarding tolerability and safety during therapy with the indicated DAAs.
Conclusions:
This present investigation is the first clinical experience in Peru with DAAs for chronic hepatitis C in HIV-positive patients. Virologic response, tolerability, and safety against daclatasvir and velpatasvir, each in conjunction or in combination with sofosbuvir, were optimal in the case series presented.
